SHALBY145.25

Shalby Limited

· Pharma & Health
₹ CrorePeersGKSLGPTHEALTHINDRAMEDCOARTEMISMEDLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹1,562 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation52.265.870.0
+ Finance Costs13.038.739.0
+ Interest Income-5.0-7.2-2.2
+ Share-based Payments1.00.00.0
+ Unrealised FX (Gain) / Loss-0.10.00.0
+ Other Non-cash Items0.0-4.5-21.4
+ Other — Cash Effects are Investing / Financing-8.6-8.0-7.5
+ Other Reconciling Items-1.10.00.0
Changes in Working Capital
+ Inventories-47.8-84.0-60.6
+ Trade Receivables — Current-32.9-31.1-56.3
+ Other Financial Assets — Current-3.71.72.2
+ Other Financial Assets — Non-current-3.83.80.6
+ Other Current Assets0.7-13.22.4
+ Other Non-current Assets-3.91.6-0.4
+ Trade Payables — Current-31.1-8.28.7
+ Other Financial Liabilities — Current-0.10.12.5
+ Other Financial Liabilities — Non-current-9.0-0.10.0
+ Other Current Liabilities-9.4-1.51.1
+ Other Non-current Liabilities-1.4-1.7-1.4
+ Provisions — Current2.42.00.0
+ Provisions — Non-current0.00.02.6
Cash from Operating Activities
Profit Before Tax (per I/S)128.255.760.657.6
+ Total Adjustments (incl. Working Capital)-88.5-45.8-20.7
Cash from Operations (pre-tax)39.79.939.9
+ Income Taxes Paid20.114.239.9
Cash from Operating Activities19.6-4.3-0.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)47.171.4149.0
+ Disp of Fixed Assets1.91.43.8
+ Acq of Investment Property0.0524.9481.0
+ Disp of Investment Property0.0519.3518.2
+ Acq of Other Long-term Assets-4.40.00.0
+ Interest Received — Investing5.17.71.7
+ Other Inflows / (Outflows) — Investing73.732.29.0
Cash from Investing Activities38.1-35.6-97.3
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.10.0
+ Proceeds from Exercise of Stock Options0.10.00.0
+ Buyback / Redemption of Own Shares205.90.00.0
+ Proceeds from Borrowings89.7152.1154.2
+ Repayment of Borrowings0.039.341.3
+ Payment of Lease Liabilities0.017.625.0
+ Payment of Finance Lease Liabilities8.9
+ Interest Paid12.934.735.1
+ Dividends Paid13.013.00.0
+ Other Inflows / (Outflows) — Financing0.10.131.6
Cash from Financing Activities-150.747.684.4
Net Changes in Cash (pre-FX)-93.07.6-12.9
Net Changes in Cash-93.07.6-12.9
Closing Cash27.2
Reference Items
EBITDA177.0132.6142.8142.8
EBITDA Margin %18.9612.2012.5112.14
Free Cash Flow (CFO − Capex)-27.5-75.8-149.1-149.1
Free Cash Flow to Equity2.2-71.2
Free Cash Flow per Basic Share-2.56-7.05-13.86-13.86
Cash Flow to Net Income0.23-2.26-0.00
Cash Paid for Taxes20.114.239.9
Cash Paid for Interest12.934.735.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.